Recent setbacks for some of AstraZeneca's (AZN) most promising experimental drugs and...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

Recent setbacks for some of AstraZeneca's (AZN) most promising experimental drugs and competition from generics mean the company may backtrack on its pledge to avoid big acquisitions. AZN has enough cash to make a small-to-medium acquisition without losing its AA- rating, says Fitch, but that kind of purchase won't be enough to compensate for the sales decline that starts this year.